Moderna (MRNA) Sentiment Can Improve with Prudent Near-Term Financial Execution - UBS
Tweet Send to a Friend
UBS analyst David Dai reiterated a Buy rating and $40.00 price target on Moderna (NASDAQ: MRNA).The analyst commented, "MRNA hosted ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
